Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Immutep Ltd ( (AU:IMM) ).
Immutep Limited announced the cessation of 1,343,856 performance rights due to a lapse in conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s operational flexibility and could influence stakeholder perceptions regarding the company’s ability to meet certain performance metrics.
More about Immutep Ltd
Immutep Limited operates in the biotechnology industry, focusing on the development of immunotherapeutic products. The company is primarily engaged in producing innovative treatments aimed at modulating the immune system to combat cancer and autoimmune diseases.
YTD Price Performance: -8.64%
Average Trading Volume: 1,000
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $291.3M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.
